Patents by Inventor Edgar Specker
Edgar Specker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240025849Abstract: The invention relates to compounds useful as inhibitors of NO production, especially inhibitors of the inducible NO synthase iNOS expressed by microglia and macrophages. The invention also relates to pharmaceutical compositions comprising these compounds and to therapeutic uses of these compounds, especially in the prophylaxis or treatment of conditions characterized by excess NO production, such as ischemic stroke and retinopathies.Type: ApplicationFiled: August 26, 2021Publication date: January 25, 2024Inventors: Helmut KETTENMANN, Susanne WOLF, Philipp JORDAN, Sabrina KLEISSLE, Martin NEUENSCHWANDER, Edgar SPECKER, Marc NAZARE
-
Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
Patent number: 11028104Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: GrantFiled: May 6, 2020Date of Patent: June 8, 2021Assignees: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Michael Bader, Edgar Specker, Susann Matthes, Anja Schütz, Keven Mallow, Maik Grohmann, Marc Nazaré -
XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME
Publication number: 20200262847Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: ApplicationFiled: May 6, 2020Publication date: August 20, 2020Applicants: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Michael BADER, Edgar SPECKER, Susann MATTHES, Anja SCHÜTZ, Keven MALLOW, Maik GROHMANN, Marc NAZARÉ -
Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
Patent number: 10683309Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: GrantFiled: July 27, 2017Date of Patent: June 16, 2020Assignees: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Michael Bader, Edgar Specker, Susann Matthes, Anja Schütz, Keven Mallow, Maik Grohmann, Marc Nazaré -
Patent number: 10596168Abstract: Chemical compounds are useful in the treatment of a subject afflicted by a thyroid disease. The compounds exhibit activity as thyroid-stimulating hormone receptor (TSHR) antagonists and can be used in the treatment of hyperthyroidism, Graves' disease, Graves' Ophthalmopathy and thyroid cancer.Type: GrantFiled: April 26, 2017Date of Patent: March 24, 2020Assignee: Forschungsverbund Berlin e.V.Inventors: Gerd Krause, Inna Hoyer, Edgar Specker, Jens Furkert, Patrick Marcinkowski, Jens-Peter Von Kries, Martin Neuenschwander, Marc Nazare
-
XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME
Publication number: 20190161503Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: ApplicationFiled: July 27, 2017Publication date: May 30, 2019Applicants: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN, FORSCHUNGSVERBUND BERLIN E.V.Inventors: Michael BADER, Edgar SPECKER, Susann MATTHES, Anja SCHÜTZ, Keven MALLOW, Maik GROHMANN, Marc NAZARÉ -
Publication number: 20190134024Abstract: Chemical compounds are useful in the treatment of a subject afflicted by a thyroid disease. The compounds exhibit activity as thyroid-stimulating hormone receptor (TSHR) antagonists and can be used in the treatment of hyperthyroidism, Graves' disease, Graves' Ophthalmopathy and thyroid cancer.Type: ApplicationFiled: April 26, 2017Publication date: May 9, 2019Applicant: Forschungsverbund Berlin e.V.Inventors: Gerd KRAUSE, Inna HOYER, Edgar SPECKER, Jens FURKERT, Patrick MARCINKOWSKI, Jens-Peter VON KRIES, Martin NEUENSCHWANDER, Marc NAZARE
-
Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
Patent number: 10214530Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: GrantFiled: February 24, 2016Date of Patent: February 26, 2019Assignee: MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZINInventors: Michael Bader, Edgar Specker, Susann Matthes, Anja Schütz, Keven Mallow, Maik Grohmann, Marc Nazaré -
Patent number: 10196423Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: May 9, 2018Date of Patent: February 5, 2019Assignee: Shire Orphan Therapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Helberg
-
Publication number: 20180334477Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: ApplicationFiled: May 9, 2018Publication date: November 22, 2018Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Helberg
-
Patent number: 9982016Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: July 10, 2017Date of Patent: May 29, 2018Assignee: Shire Orphan Therapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME
Publication number: 20180051025Abstract: The invention relates to a xanthine derivative defined by chemical formula I or a salt thereof, its use as a medicament, especially for use in the treatment of serotonin-related diseases or disorders, and a pharmaceutical preparation comprising the xanthine derivative. The novel xanthine compounds are capable of inhibiting tryptophan hydroxylases (TPH) involved in the biosynthesis of serotonin and are effective in influencing the serotonin level in the body.Type: ApplicationFiled: February 24, 2016Publication date: February 22, 2018Applicants: Max-Delbrück-Centrum für Molekulare Medizin, Forschungsverbund Berlin e.V.Inventors: Michael BADER, Edgar SPECKER, Susann MATTHES, Anja SCHÜTZ, Keven MALLOW, Maik GROHMANN, Marc NAZARÉ -
Publication number: 20170313743Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: ApplicationFiled: July 10, 2017Publication date: November 2, 2017Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Patent number: 9745344Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: August 12, 2015Date of Patent: August 29, 2017Assignee: Shire Orphan Therapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Patent number: 9458198Abstract: Disclosed are cyclic, peptide-based novel compounds having NPR-B agonistic activity. Preferred compounds are cyclic peptides containing conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds. In some embodiments, provided herein are a cyclic peptide compound with a ring size that is significantly reduced as compared to known NPR-B agonists, such as CNP.Type: GrantFiled: June 12, 2013Date of Patent: October 4, 2016Assignee: Shire Orphan Therapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Publication number: 20160194357Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: ApplicationFiled: August 12, 2015Publication date: July 7, 2016Inventors: Frank Ostercamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Patent number: 9169293Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: August 28, 2013Date of Patent: October 27, 2015Assignee: Shire Orphan Thereapies GmbHInventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Publication number: 20130345394Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: ApplicationFiled: August 28, 2013Publication date: December 26, 2013Applicant: Alcon Research, Ltd.Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Patent number: 8546523Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: GrantFiled: September 23, 2010Date of Patent: October 1, 2013Assignee: Alcon Research, Ltd.Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Uwe Richter, Bernadett Simon, Edgar Specker, Markus Woischnik, Mark R. Hellberg
-
Publication number: 20110077381Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.Type: ApplicationFiled: September 23, 2010Publication date: March 31, 2011Applicant: ALCON RESEARCH, LTD.Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Uwe Richter, Bernadett Simon, Edgar Specker, Markus Woischnik, Mark R. Hellberg
